Biomarker & Intervention Discovery

Cervical Cancer

This page lists 10 druggable gene targets, 44 approved or trial-tested drug candidates and 5 recent clinical trials for Cervical Cancer, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Plain-language summary → New Treatments for Cervical Cancer (2026): Drugs in Trials

US DALYs227.1KWHO GHE 2021 · all ages
Global DALYs11.95MWHO GHE 2021 · worldwide
US mortality6,640 deaths/yrWHO GHE 2021
Global mortality337.9K deaths/yrWHO GHE 2021 · worldwide
NIH funding$135MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionCIN2/3 (precancerous): spontaneous regression in 40-60% of CIN2 without treatment; CIN3: regression in ~30%; invasive…
Best-intervention remissionEarly-stage (IA-IIA): radical hysterectomy or chemoradiation — 80-90% 5-year survival; locally advanced (IIB-IVA):…
Gap sizeVery large from a prevention standpoint — HPV vaccination and screening can prevent most cervical cancers but coverage…
Primary barrieraccess (prevention)
Full remission profile →
Research Tracker Chronic Disease Interventions Cervical Cancer

Remission & chronicity

Spontaneous remission
CIN2/3 (precancerous): spontaneous regression in 40-60% of CIN2 without treatment; CIN3: regression in ~30%; invasive cervical cancer: no spontaneous regression
Best-intervention remission
Early-stage (IA-IIA): radical hysterectomy or chemoradiation — 80-90% 5-year survival; locally advanced (IIB-IVA): cisplatin-based chemoradiation — 60-70% 5-year survival; metastatic with pembrolizumab + chemotherapy ± bevacizumab: 24.4 vs 16.3 months OS (KEYNOTE-826); ENGOT-cx11/GOG-3047: cemiplimab + chemo superior
Gap size
Very large from a prevention standpoint — HPV vaccination and screening can prevent most cervical cancers but coverage is dramatically insufficient
Primary barrier
access (prevention)
HPV vaccination prevents ~90% of cervical cancers caused by HPV 16/18 (and gardasil 9 covers 9 types); cervical cancer screening (Pap + HPV co-testing) prevents invasive cancer; yet globally only 10% of women in LMICs have received the HPV vaccine; in the US, HPV vaccination coverage remains at ~60% of adolescents

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

CD274 200CDKN2A 29EGFR 403F3 155KDR 382PDCD1 52PIK3CA 444RB1 65TP53 652VEGFA 207

CD274

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ATEZOLIZUMAB ? unclear Mechanistic DGIdb
DURVALUMAB ↓ inhibits Mechanistic DGIdb
PEMETREXED DISODIUM ? unclear Mechanistic DGIdb
BETIFISOLIMAB ? unclear Mechanistic DGIdb
AVELUMAB ? unclear Mechanistic DGIdb
SOCAZOLIMAB ↓ inhibits Mechanistic DGIdb
NIVOLUMAB ? unclear Mechanistic DGIdb
COSIBELIMAB ? unclear Mechanistic DGIdb
DANBURSTOTUG ↓ inhibits Mechanistic DGIdb
ENVAFOLIMAB ? unclear Mechanistic DGIdb
PACMILIMAB ~ modulates Mechanistic DGIdb
CA-170 ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
TISLELIZUMAB ? unclear Mechanistic DGIdb
ERFONRILIMAB ↓ inhibits Mechanistic DGIdb
TREMELIMUMAB ? unclear Mechanistic DGIdb
ANTI-PD-L1 MONOCLONAL ANTIBODY FAZ053 ? unclear Mechanistic DGIdb
BINTRAFUSP ALFA ? unclear Mechanistic DGIdb
IPILIMUMAB ? unclear Mechanistic DGIdb
CEMIPLIMAB ? unclear Mechanistic DGIdb
ADEBRELIMAB ↓ inhibits Mechanistic DGIdb
SUGEMALIMAB ~ modulates Mechanistic DGIdb
LODAPOLIMAB ? unclear Mechanistic DGIdb
INCB-086550 ↓ inhibits Mechanistic DGIdb
PIDILIZUMAB ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
ANTI-PD-L1 MONOCLONAL ANTIBODY MDX-1105 ? unclear Mechanistic DGIdb
PENPULIMAB ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ? unclear Mechanistic DGIdb
ANTI-LAG-3/PD-L1 BISPECIFIC ANTIBODY FS118 ? unclear Mechanistic DGIdb
CHEMBL3582257 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3582256 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3582255 ↓ inhibits Mechanistic 1010.0 nM (IC50) ChEMBL
CHEMBL3582254 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL3582253 ↓ inhibits Mechanistic 110.0 nM (IC50) ChEMBL
CHEMBL3582252 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL4081869 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL
CHEMBL4099869 ↓ inhibits Mechanistic 146.0 nM (IC50) ChEMBL
CHEMBL4089730 ↓ inhibits Mechanistic 18.0 nM (IC50) ChEMBL
CHEMBL4061613 ↓ inhibits Mechanistic 6.0 nM (IC50) ChEMBL

Showing top 40 of 200 agents ranked by evidence tier.

CDKN2A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
(10R)-10-METHYL-3-(6-METHYLPYRIDIN-3-YL)-9,10,11,12-TETRAHYDRO-8H-[1,4]DIAZEPINO[5',6':4,5]THIENO[3,2-F]QUINOLIN-8-ONE ? unclear Mechanistic DGIdb
LETROZOLE ? unclear Mechanistic DGIdb
PALBOCICLIB ? unclear Mechanistic DGIdb
VEMURAFENIB ? unclear Mechanistic DGIdb
PF-04691502 ? unclear Mechanistic DGIdb
SIROLIMUS ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
TEMOZOLOMIDE ? unclear Mechanistic DGIdb
DABRAFENIB ? unclear Mechanistic DGIdb
ABEMACICLIB ? unclear Mechanistic DGIdb
POLO-LIKE KINASE 1 INHIBITOR GSK461364 ? unclear Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
CETUXIMAB ? unclear Mechanistic DGIdb
IMMUNE CHECKPOINT INHIBITOR ? unclear Mechanistic DGIdb
COBIMETINIB ? unclear Mechanistic DGIdb
ULIXERTINIB ? unclear Mechanistic DGIdb
SAPANISERTIB ? unclear Mechanistic DGIdb
ALVOCIDIB ? unclear Mechanistic DGIdb
MILCICLIB ? unclear Mechanistic DGIdb
HMN-214 ? unclear Mechanistic DGIdb
TRAMETINIB DIMETHYL SULFOXIDE ? unclear Mechanistic DGIdb
RIBOCICLIB ? unclear Mechanistic DGIdb
GEMCITABINE ? unclear Mechanistic DGIdb
ILORASERTIB ? unclear Mechanistic DGIdb
RONICICLIB ? unclear Mechanistic DGIdb
PF-00477736 ? unclear Mechanistic DGIdb
PANITUMUMAB ? unclear Mechanistic DGIdb
BUPARLISIB ? unclear Mechanistic DGIdb
EVEROLIMUS ? unclear Mechanistic DGIdb

EGFR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AUMOLERTINIB ↓ inhibits Mechanistic DGIdb
AFATINIB ↓ inhibits Mechanistic DGIdb
ABIVERTINIB ↓ inhibits Mechanistic DGIdb
FUTUXIMAB ↓ inhibits Mechanistic DGIdb
RINDOPEPIMUT ? unclear Mechanistic DGIdb
PD-0166285 HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
OLMUTINIB ↓ inhibits Mechanistic DGIdb
OSIMERTINIB MESYLATE ↓ inhibits Mechanistic DGIdb
ABIVERTINIB MALEATE ↓ inhibits Mechanistic DGIdb
ROCILETINIB ↓ inhibits Mechanistic DGIdb
GEFITINIB ↓ inhibits Mechanistic 515.0 nM (IC50) DGIdb
MATUZUMAB ↓ inhibits Mechanistic DGIdb
GRACILIN J ? unclear Mechanistic DGIdb
NIMOTUZUMAB ↓ inhibits Mechanistic DGIdb
LAZERTINIB ↓ inhibits Mechanistic DGIdb
LAPATINIB ↓ inhibits Mechanistic DGIdb
PANITUMUMAB ↓ inhibits Mechanistic DGIdb
DOSIMERTINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 17B [PMID: 35286086] ↓ inhibits Mechanistic DGIdb
IBRUTINIB ↓ inhibits Mechanistic DGIdb
POZIOTINIB ↓ inhibits Mechanistic DGIdb
TARLOXOTINIB ↓ inhibits Mechanistic DGIdb
OSIMERTINIB ↓ inhibits Mechanistic DGIdb
DACOMITINIB ANHYDROUS ↓ inhibits Mechanistic DGIdb
ICOTINIB HYDROCHLORIDE ? unclear Mechanistic DGIdb
MIFANERTINIB ↓ inhibits Mechanistic DGIdb
NAQUOTINIB ↓ inhibits Mechanistic DGIdb
BMS-690514 ↓ inhibits Mechanistic DGIdb
NAZARTINIB ↓ inhibits Mechanistic DGIdb
CUDC-101 ↓ inhibits Mechanistic DGIdb
DEHYDRATED ALCOHOL ? unclear Mechanistic DGIdb
BEFOTERTINIB ↓ inhibits Mechanistic DGIdb
NECITUMUMAB ↓ inhibits Mechanistic DGIdb
CHEMBL:CHEMBL1914653 ? unclear Mechanistic DGIdb
LAPRITUXIMAB EMTANSINE ? unclear Mechanistic DGIdb
INDIUM-111 ? unclear Mechanistic DGIdb
AV-412 ↓ inhibits Mechanistic DGIdb
CETUXIMAB ↓ inhibits Mechanistic DGIdb
EPIREGULIN ? unclear Mechanistic DGIdb

Showing top 40 of 403 agents ranked by evidence tier.

F3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TISOTUMAB VEDOTIN ~ modulates Mechanistic DGIdb
MORAB-066 ? unclear Mechanistic DGIdb
ANTI-TF MONOCLONAL ANTIBODY ALT-836 ? unclear Mechanistic DGIdb
ANPOCOGIN ? unclear Mechanistic DGIdb
SIMVASTATIN ? unclear Mechanistic DGIdb
CHEMBL377280 ↓ inhibits Mechanistic 43.0 nM (IC50) ChEMBL
CHEMBL203668 ↓ inhibits Mechanistic 170.0 nM (IC50) ChEMBL
CHEMBL202883 ↓ inhibits Mechanistic 63.0 nM (IC50) ChEMBL
CHEMBL204800 ↓ inhibits Mechanistic 240.0 nM (IC50) ChEMBL
CHEMBL381678 ↓ inhibits Mechanistic 1600.0 nM (IC50) ChEMBL
CHEMBL201514 ↓ inhibits Mechanistic 600.0 nM (IC50) ChEMBL
CHEMBL381881 ↓ inhibits Mechanistic 110.0 nM (IC50) ChEMBL
CHEMBL201853 ↓ inhibits Mechanistic 92.0 nM (IC50) ChEMBL
CHEMBL382573 ↓ inhibits Mechanistic 16.0 nM (IC50) ChEMBL
CHEMBL205123 ↓ inhibits Mechanistic 20.0 nM (IC50) ChEMBL
CHEMBL381740 ↓ inhibits Mechanistic 16.0 nM (IC50) ChEMBL
CHEMBL1162921 ↓ inhibits Mechanistic 380.0 nM (IC50) ChEMBL
CHEMBL202399 ↓ inhibits Mechanistic 590.0 nM (IC50) ChEMBL
CHEMBL381021 ↓ inhibits Mechanistic 180.0 nM (IC50) ChEMBL
CHEMBL201901 ↓ inhibits Mechanistic 31.0 nM (IC50) ChEMBL
CHEMBL371638 ↓ inhibits Mechanistic 27.0 nM (IC50) ChEMBL
CHEMBL204084 ↓ inhibits Mechanistic 17.0 nM (IC50) ChEMBL
CHEMBL189175 ↓ inhibits Mechanistic 180.0 nM (IC50) ChEMBL
CHEMBL204231 ↓ inhibits Mechanistic 150.0 nM (IC50) ChEMBL
CHEMBL382807 ↓ inhibits Mechanistic 47.0 nM (IC50) ChEMBL
CHEMBL381897 ↓ inhibits Mechanistic 570.0 nM (IC50) ChEMBL
CHEMBL381896 ↓ inhibits Mechanistic 210.0 nM (IC50) ChEMBL
CHEMBL201835 ↓ inhibits Mechanistic 130.0 nM (IC50) ChEMBL
CHEMBL202505 ↓ inhibits Mechanistic 120.0 nM (IC50) ChEMBL
CHEMBL382572 ↓ inhibits Mechanistic 48.0 nM (IC50) ChEMBL
CHEMBL204602 ↓ inhibits Mechanistic 290.0 nM (IC50) ChEMBL
CHEMBL204858 ↓ inhibits Mechanistic 190.0 nM (IC50) ChEMBL
CHEMBL383717 ↓ inhibits Mechanistic 97.0 nM (IC50) ChEMBL
CHEMBL204654 ↓ inhibits Mechanistic 67.0 nM (IC50) ChEMBL
CHEMBL380534 ↓ inhibits Mechanistic 36.0 nM (IC50) ChEMBL
CHEMBL204653 ↓ inhibits Mechanistic 73.0 nM (IC50) ChEMBL
CHEMBL381156 ↓ inhibits Mechanistic 2400.0 nM (IC50) ChEMBL
CHEMBL438808 ↓ inhibits Mechanistic 130.0 nM (IC50) ChEMBL
CHEMBL377082 ↓ inhibits Mechanistic 4.0 nM (Ki) ChEMBL
CHEMBL206387 ↓ inhibits Mechanistic 2.0 nM (Ki) ChEMBL

Showing top 40 of 155 agents ranked by evidence tier.

KDR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CEDIRANIB ↓ inhibits Mechanistic DGIdb
XL820 ↓ inhibits Mechanistic DGIdb
EUPATORIN ↓ inhibits Mechanistic DGIdb
CABOZANTINIB S-MALATE ↓ inhibits Mechanistic DGIdb
TOCERANIB ↓ inhibits Mechanistic DGIdb
LAZERTINIB ↓ inhibits Mechanistic DGIdb
VADIMEZAN ? unclear Mechanistic DGIdb
VANDETANIB ↓ inhibits Mechanistic 70.0 nM (IC50) DGIdb
SURUFATINIB ↓ inhibits Mechanistic DGIdb
CANLITINIB ↓ inhibits Mechanistic DGIdb
FORETINIB ↓ inhibits Mechanistic DGIdb
PEGPLERANIB SODIUM ? unclear Mechanistic DGIdb
REGORAFENIB ↓ inhibits Mechanistic DGIdb
LINIFANIB ↓ inhibits Mechanistic DGIdb
MOTESANIB ↓ inhibits Mechanistic DGIdb
ILORASERTIB ↓ inhibits Mechanistic DGIdb
SUNITINIB ↓ inhibits Mechanistic DGIdb
COMPOUND 13A [PMID: 23639540] ↓ inhibits Mechanistic DGIdb
PONATINIB ↓ inhibits Mechanistic DGIdb
XL-820 ↓ inhibits Mechanistic DGIdb
BX-795 ↓ inhibits Mechanistic DGIdb
TELATINIB ↓ inhibits Mechanistic DGIdb
SORAFENIB ↓ inhibits Mechanistic DGIdb
LUCITANIB ↓ inhibits Mechanistic DGIdb
PP-121 ↓ inhibits Mechanistic DGIdb
NINGETINIB ↓ inhibits Mechanistic DGIdb
TINENGOTINIB ↓ inhibits Mechanistic DGIdb
BJ-2412 ↓ inhibits Mechanistic DGIdb
VEGF RECEPTOR TYROSINE KINASE INHIBITOR III ↓ inhibits Mechanistic DGIdb
PF-00337210 ↓ inhibits Mechanistic DGIdb
AST-487 ↓ inhibits Mechanistic DGIdb
RAMUCIRUMAB ↓ inhibits Mechanistic DGIdb
AG-13958 ↓ inhibits Mechanistic DGIdb
SU-14813 ↓ inhibits Mechanistic DGIdb
X-82 ↓ inhibits Mechanistic DGIdb
ENMD-2076 ↓ inhibits Mechanistic DGIdb
GOLVATINIB ↓ inhibits Mechanistic DGIdb
CENISERTIB ? unclear Mechanistic DGIdb
LENVATINIB ↓ inhibits Mechanistic DGIdb
SULFATINIB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 382 agents ranked by evidence tier.

PDCD1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CAMRELIZUMAB ↓ inhibits Mechanistic DGIdb
AMP-224 ? unclear Mechanistic DGIdb
PEMBROLIZUMAB ↓ inhibits Mechanistic DGIdb
SERPLULIMAB ? unclear Mechanistic DGIdb
ENLONSTOBART ? unclear Mechanistic DGIdb
CEMIPLIMAB ↓ inhibits Mechanistic DGIdb
CT-011 ? unclear Mechanistic DGIdb
SASANLIMAB ? unclear Mechanistic DGIdb
PUCOTENLIMAB ↓ inhibits Mechanistic DGIdb
TISLELIZUMAB ? unclear Mechanistic DGIdb
TEBOTELIMAB ↓ inhibits Mechanistic DGIdb
CADONILIMAB ? unclear Mechanistic DGIdb
SPARTALIZUMAB ? unclear Mechanistic DGIdb
MEDI0680 ? unclear Mechanistic DGIdb
AUNP-12 ? unclear Mechanistic DGIdb
DOSTARLIMAB ? unclear Mechanistic DGIdb
TORIPALIMAB ↓ inhibits Mechanistic DGIdb
CC-90006 ? unclear Mechanistic DGIdb
CETRELIMAB ↓ inhibits Mechanistic DGIdb
PROGRAMMED CELL DEATH 1 LIGAND 1 ? unclear Mechanistic DGIdb
ANTI-PD-1 MONOCLONAL ANTIBODY SYM021 ? unclear Mechanistic DGIdb
CS-1003 ↓ inhibits Mechanistic DGIdb
EZABENLIMAB ? unclear Mechanistic DGIdb
PROLGOLIMAB ? unclear Mechanistic DGIdb
LIPUSTOBART ? unclear Mechanistic DGIdb
PENPULIMAB ↓ inhibits Mechanistic DGIdb
BALSTILIMAB ? unclear Mechanistic DGIdb
GEPTANOLIMAB ? unclear Mechanistic DGIdb
IVONESCIMAB ? unclear Mechanistic DGIdb
SINTILIMAB ? unclear Mechanistic DGIdb
LORIGERLIMAB ? unclear Mechanistic DGIdb
FINOTONLIMAB ↓ inhibits Mechanistic DGIdb
RETIFANLIMAB ? unclear Mechanistic DGIdb
PUCOLENTIMAB ? unclear Mechanistic DGIdb
BINTRAFUSP ALFA ? unclear Mechanistic DGIdb
IPAROMLIMAB ? unclear Mechanistic DGIdb
PIMIVALIMAB ↓ inhibits Mechanistic DGIdb
VUDALIMAB ? unclear Mechanistic DGIdb
APL-501 ↓ inhibits Mechanistic DGIdb
ZIMBERELIMAB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 52 agents ranked by evidence tier.

PIK3CA

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SURAMIN ? unclear Mechanistic DGIdb
TEMSIROLIMUS ? unclear Mechanistic DGIdb
RIGOSERTIB ↓ inhibits Mechanistic DGIdb
NEOLYMPHOSTIN A ↓ inhibits Mechanistic DGIdb
INAVOLISIB ↓ inhibits Mechanistic DGIdb
RIGOSERTIB SODIUM ? unclear Mechanistic DGIdb
TAK-733 ? unclear Mechanistic DGIdb
APILIMOD DIMESYLATE CAPSULE ? unclear Mechanistic DGIdb
COMPOUND 15A [PMID: 32069401] ↓ inhibits Mechanistic DGIdb
COMPOUND 41 [PMID: 31855425] ↓ inhibits Mechanistic DGIdb
ERDAFITINIB ? unclear Mechanistic DGIdb
RIBOCICLIB ? unclear Mechanistic DGIdb
BRAFV600/PI3K INHIBITOR ASN003 ? unclear Mechanistic DGIdb
GSK2636771 ↓ inhibits Mechanistic DGIdb
ZINC SULFATE ANHYDROUS ? unclear Mechanistic DGIdb
EVEROLIMUS ? unclear Mechanistic DGIdb
COPANLISIB ↓ inhibits Mechanistic DGIdb
TANESPIMYCIN ? unclear Mechanistic DGIdb
CAPIVASERTIB ? unclear Mechanistic DGIdb
SAMOTOLISIB ↓ inhibits Mechanistic DGIdb
COPANLISIB HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PAXALISIB ↓ inhibits Mechanistic DGIdb
U0126 ? unclear Mechanistic DGIdb
PILARALISIB ↓ inhibits Mechanistic DGIdb
M-2698 ? unclear Mechanistic DGIdb
GSK2334470 ? unclear Mechanistic DGIdb
BIMIRALISIB ↓ inhibits Mechanistic DGIdb
PALBOCICLIB ? unclear Mechanistic DGIdb
SONOLISIB ↓ inhibits Mechanistic 88.0 nM (IC50) DGIdb
VULOLISIB ↓ inhibits Mechanistic DGIdb
ALPELISIB ↓ inhibits Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
COMPOUND 27 [PMID: 35834807] ↓ inhibits Mechanistic DGIdb
MILTEFOSINE ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
ACALISIB ↓ inhibits Mechanistic DGIdb
GEDATOLISIB ↓ inhibits Mechanistic DGIdb
VS-5584 ↓ inhibits Mechanistic DGIdb
XRD-0394 ↓ inhibits Mechanistic DGIdb
IZORLISIB ? unclear Mechanistic DGIdb

Showing top 40 of 444 agents ranked by evidence tier.

RB1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TOPOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb
VORINOSTAT ? unclear Mechanistic DGIdb
FULVESTRANT ? unclear Mechanistic DGIdb
ALPELISIB ? unclear Mechanistic DGIdb
REBEMADLIN ? unclear Mechanistic DGIdb
TRICHOSTATIN A ? unclear Mechanistic DGIdb
RIBOCICLIB ? unclear Mechanistic DGIdb
JQ1 ? unclear Mechanistic DGIdb
GEMCITABINE ? unclear Mechanistic DGIdb
PALBOCICLIB ? unclear Mechanistic DGIdb
LORLATINIB ? unclear Mechanistic DGIdb
SELICICLIB ? unclear Mechanistic DGIdb
VCN-01 ? unclear Mechanistic DGIdb
NIRAPARIB ? unclear Mechanistic DGIdb
TAZEMETOSTAT ? unclear Mechanistic DGIdb
CHECKPOINT KINASE INHIBITOR AZD7762 ? unclear Mechanistic DGIdb
TRAMETINIB DIMETHYL SULFOXIDE ? unclear Mechanistic DGIdb
FOSTAMATINIB ? unclear Mechanistic DGIdb
BARASERTIB ? unclear Mechanistic DGIdb
R547 ? unclear Mechanistic DGIdb
VOLASERTIB ? unclear Mechanistic DGIdb
LETROZOLE ? unclear Mechanistic DGIdb
PEMRAMETOSTAT ? unclear Mechanistic DGIdb
PICTILISIB ? unclear Mechanistic DGIdb
VEMURAFENIB ? unclear Mechanistic DGIdb
DECITABINE ? unclear Mechanistic DGIdb
SIROLIMUS ? unclear Mechanistic DGIdb
BAY 61-3606 ? unclear Mechanistic DGIdb
ALISERTIB ? unclear Mechanistic DGIdb
TRILACICLIB ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
DALPICICLIB ? unclear Mechanistic DGIdb
AURORA A KINASE INHIBITOR LY3295668 ? unclear Mechanistic DGIdb
PACLITAXEL PROTEIN-BOUND ? unclear Mechanistic DGIdb
OLAPARIB ? unclear Mechanistic DGIdb
ENTINOSTAT ? unclear Mechanistic DGIdb
TRETINOIN ? unclear Mechanistic DGIdb
TALAZOPARIB ? unclear Mechanistic DGIdb
LARGAZOLE ? unclear Mechanistic DGIdb
AURORA A KINASE INHIBITOR LY3295668 ERBUMINE ? unclear Mechanistic DGIdb

Showing top 40 of 65 agents ranked by evidence tier.

TP53

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PIRARUBICIN ? unclear Mechanistic DGIdb
OXALIPLATIN ? unclear Mechanistic DGIdb
SIREMADLIN ↓ inhibits Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
DAUNORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL260560 ? unclear Mechanistic DGIdb
MELPHALAN ? unclear Mechanistic DGIdb
LAPACHONE ? unclear Mechanistic DGIdb
VITAMIN K3 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL260451 ? unclear Mechanistic DGIdb
DINOSEB ? unclear Mechanistic DGIdb
RIMCAZOLE ? unclear Mechanistic DGIdb
TRACAZOLATE ? unclear Mechanistic DGIdb
CAPIVASERTIB ? unclear Mechanistic DGIdb
AZD7648 ? unclear Mechanistic DGIdb
QUINALIZARIN ? unclear Mechanistic DGIdb
INOSITOL ? unclear Mechanistic DGIdb
ECONAZOLE NITRATE ? unclear Mechanistic DGIdb
L-733,060 ? unclear Mechanistic DGIdb
U50488 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL260028 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL601140 ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL408563 ? unclear Mechanistic DGIdb
ENALAPRIL MALEATE ? unclear Mechanistic DGIdb
HOMIDIUM BROMIDE ? unclear Mechanistic DGIdb
IOXYNIL ? unclear Mechanistic DGIdb
ACALABRUTINIB ? unclear Mechanistic DGIdb
INDOPROFEN ? unclear Mechanistic DGIdb
MERCAPTOPURINE ? unclear Mechanistic DGIdb
AUTOLOGOUS DENDRITIC CELLS TRANSDUCED WITH WILD-TYPE P53 ADENOVIRUS VACCINE ? unclear Mechanistic DGIdb
ZIRAM ? unclear Mechanistic DGIdb
IFOSFAMIDE ? unclear Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
SOTULETINIB ? unclear Mechanistic DGIdb
SERTRALINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
PD166285 ? unclear Mechanistic DGIdb
SAPANISERTIB ? unclear Mechanistic DGIdb
ENZALUTAMIDE ? unclear Mechanistic DGIdb
PYRITHIONE ZINC ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1169388 ? unclear Mechanistic DGIdb

Showing top 40 of 652 agents ranked by evidence tier.

VEGFA

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
BEVASIRANIB ? unclear Mechanistic DGIdb
RANIBIZUMAB ↓ inhibits Mechanistic DGIdb
CP-547632 ? unclear Mechanistic DGIdb
EW-A-401 ? unclear Mechanistic DGIdb
BEVACIZUMAB 111IN ~ modulates Mechanistic DGIdb
FENOFIBRATE MICRONIZED ? unclear Mechanistic DGIdb
PEGAPTANIB ↓ inhibits Mechanistic DGIdb
DEXAMETHASONE ? unclear Mechanistic DGIdb
SQUALAMINE ? unclear Mechanistic DGIdb
AFLIBERCEPT ↓ inhibits Mechanistic DGIdb
PAZOPANIB ? unclear Mechanistic DGIdb
BEVACIZUMAB GAMMA ~ modulates Mechanistic DGIdb
CILOSTAZOL ? unclear Mechanistic DGIdb
ADALIMUMAB ? unclear Mechanistic DGIdb
MUPARFOSTAT ↓ inhibits Mechanistic DGIdb
SILDENAFIL ? unclear Mechanistic DGIdb
PENTOSAN POLYSULFATE ? unclear Mechanistic DGIdb
THALIDOMIDE ? unclear Mechanistic DGIdb
RISUTEGANIB ? unclear Mechanistic DGIdb
SELECTIVE CYTOKINE INHIBITORY DRUG CC-1088 ? unclear Mechanistic DGIdb
PHENETHYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
EMVODODSTAT ? unclear Mechanistic DGIdb
CARFILZOMIB ? unclear Mechanistic DGIdb
FARICIMAB ↓ inhibits Mechanistic DGIdb
ALBUTEROL SULFATE ? unclear Mechanistic DGIdb
LENALIDOMIDE ↓ inhibits Mechanistic DGIdb
SUNITINIB ? unclear Mechanistic DGIdb
SHARK CARTILAGE EXTRACT AE-941 ? unclear Mechanistic DGIdb
NM-3 ? unclear Mechanistic DGIdb
DILPACIMAB ? unclear Mechanistic DGIdb
PEMETREXED DISODIUM ? unclear Mechanistic DGIdb
BI-836880 ? unclear Mechanistic DGIdb
BROLUCIZUMAB ↓ inhibits Mechanistic DGIdb
DOMATINOSTAT ? unclear Mechanistic DGIdb
ANTHRACYCLINE ANTINEOPLASTIC ANTIBIOTIC ? unclear Mechanistic DGIdb
VEGF/HGF-TARGETING DARPIN MP0250 ? unclear Mechanistic DGIdb
WARFARIN ? unclear Mechanistic DGIdb
CELECOXIB ? unclear Mechanistic DGIdb
NAVICIXIZUMAB ? unclear Mechanistic DGIdb
VEGLIN ? unclear Mechanistic DGIdb

Showing top 40 of 207 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Cervical Cancer: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Recruiting
NCT05686226 Phase: 2 Started: 2023-03-07

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR...

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers Recruiting
NCT05639972 Phase: 1/2 Started: 2025-08-11

The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is to shrink or eliminat...

AK105 Combined With Anlotinib in Patients With Cervical Cancer Active Not Recruiting
NCT05137171 Phase: 2 Started: 2022-05-02

The purpose of this study is to evaluate the efficacy and safety of AK105 (anti-PD-1 mab) combined with Anlotinib Hydrochloride in the treatment of persistent, recurrent and metastatic cervical cancer.

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial Active Not Recruiting
NCT05237947 Phase: 4 Started: 2022-03-01

This phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, mainly in the genital or...

Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer Recruiting
NCT07876154 Phase: 2 Started: 2025-09-25

The goal of this clinical trial is to learn if Iparomlimab/Tuvonralimab combined with nab-paclitaxel and cisplatin as neoadjuvant treatment can treat locally advanced cervical cancer in adult female patients. It will also learn about the safety of this combination regimen. The main questions it aims...

Agents Found By Disease-Level Search

Searched directly from “Cervical Cancer” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

44 agents shown (approved or with trial evidence) — 33 not found by the gene-target search above.

cisplatin

Phase 3 · 8 trials · source: ClinicalTrials.gov, Open Targets
NCT00006248 NCT01088347 NCT00005965

Pembrolizumab

Phase 3 · 6 trials · source: ClinicalTrials.gov, Open Targets
NCT02432963 NCT05269381 NCT05104567

Cetuximab

Phase 2 · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT01647555 NCT05104567 NCT02282371

fluorouracil

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00006248 NCT00006038 NCT05355701

docetaxelNOT in gene-target list

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT00003565 NCT00006038 NCT00813072

paclitaxelNOT in gene-target list

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00006248 NCT00003592 NCT07290621

Carboplatin

Phase 3 · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT07290621 NCT01490749 NCT00498953

Nivolumab

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT04080804 NCT03416244

Ipilimumab

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT04080804 NCT03416244

methotrexate

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00003592 NCT00006033

IrinotecanNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00165464 NCT00813072

SeismofitNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07159711

Modified Vaccinia Virus Ankara Vaccine Expressing p53NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02432963

Hyperpolarized 13C PyruvateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04951921

Novel nano-scintillator fiber-optic dosimeter (nanoFOD)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02040155

Tislelizumab (BGB-A317) with chemoradiotherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06430658

cadonilimab (AK104)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04220307

INCB099280NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04242199

RelatlimabNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04080804

mapatumumabNOT in gene-target list

Phase 1/2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01088347

CyclophosphamideNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05269381

Neoantigen Peptide VaccineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05269381

SargramostimNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05269381

Computed TomographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05269381

pegenzileukin (THOR-707)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05104567

Cervarix™ (HPV-16/18 L1 VLP AS04)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00492544

bryostatin 1NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00005965

vaccinationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05938192

Toripalimab

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07290621

COPAN 552c.80 FLOQSwabNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05453006

Autologous DC vaccineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04166006

Interleukin-2NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04166006

Lenvatinib

Phase 2/3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT04199104

Erlotinib

Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00570232

Genetically modified CTLsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00516087

everolimus (RAD001)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT01490749

XELOXNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01490749

alpelisib (BYL719)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT02282371

NIRIS 1300eNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01766284

Carboplatin, 5FU concomitantNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00609284

OlympusNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02182804

CellvizioNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02182804

BL-M17D1NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06500052

Cervarix®, GlaxoSmithKlineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02296255

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.